Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 6/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329573 | 0.83 | BCHE (0.47) | BCHEHTR2CTACR1ARCCKBR | |
| SCHEMBL16684897 | 0.83 | CCKBR (0.39) | BCHEHTR2CHTR2AHTR2BHTR5A | |
| SCHEMBL6332268 | 0.77 | BCHE (0.44) | BCHEHTR2CCCKBR | |
| SCHEMBL6648615 | 0.77 | BCHE (0.50) | BCHEHTR2CHTR5AARCCKBR | |
| SCHEMBL10841290 | 0.77 | BCHE (0.44) | BCHEHTR2CCCKBR | |
| SCHEMBL3693863 | 0.77 | BCHE (0.44) | BCHEHTR2CHTR2ACCKBR | |
| SCHEMBL23308864 | 0.75 | BCHE (0.45) | BCHEHTR2CARCCKBR | |
| SCHEMBL6045967 | 0.75 | BCHE (0.48) | BCHEHTR2ACCKBR | |
| SCHEMBL20570921 | 0.75 | BCHE (0.57) | BCHEHTR5AARCCKBRPGR | |
| SCHEMBL6045958 | 0.75 | BCHE (0.48) | BCHECCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116874-B1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | ABBVIE DEUTSCHLAND (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20170112851-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-04-27 | — | — | US | disclosed |
| EP-3116874-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-9540376-B2 | Hexahydrodiazepinoquinolines carrying a substituted alkyl radical | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20150259346-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2015136091-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112851-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | HTR2C, HTR2A, HTR3C | BCHE 1182/4885HTR2C 1/4885HTR2A 2/4885 |
| US-20150259346-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | HTR2C, HTR2A, HTR3C | BCHE 1182/4885HTR2C 1/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.